Get the tools used by (smart)2 investors.

EV / EBIT for Cardiff Oncology Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

CRDF: Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company’s lead drug candidate is Onvansertib, an oral, small molecu...

2.88 USD
Price
USD
Fair Value
Upside
2.01 - 5.64
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Cardiff Oncology Inc's EV / EBIT:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-40.0x-30.0x-20.0x-10.0x0.0x

Performance Summary
  • Cardiff Oncology's latest twelve months ev / ebit is -2.1x
  • Cardiff Oncology's ev / ebit for fiscal years ending December 2020 to 2024 averaged -8.2x.
  • Cardiff Oncology's operated at median ev / ebit of -2.1x from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Cardiff Oncology's ev / ebit peaked in December 2022 at 1.2x.
  • Cardiff Oncology's ev / ebit hit its 5-year low in December 2020 of -35.6x.
  • Cardiff Oncology's ev / ebit decreased in 2020 (-35.6x, +23,413.9%), 2023 (0.3x, -76.2%), and 2024 (-2.1x, -815.8%) and increased in 2021 (-4.7x, -86.8%) and 2022 (1.2x, -126.0%).

How does Cardiff Oncology's EV / EBIT benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Cardiff Oncology Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: EV / EBIT

Hide this widget
ev_to_ebit_ltm
Slug
number
Datatype
text
Format
current
Default Period
FY, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to EV / EBIT in the valuation category include:

View Full List

Search for metric or datapoint

EV / EBIT

Measures the dollars in Enterprise Value for each dollar of EBIT over the last twelve months.

Definition of EV / EBIT

Hide this widget

Enterprise Value / LTM EBIT measures the dollars in Enterprise Value for each dollar of EBIT earned over the last 12 months. EBIT stands for Earnings before Interest and Taxes.

EV / LTM EBIT = Enterprise Value / LTM EBIT

Applying this formula, Cardiff Oncology’s EV/EBIT Ratio is calculated below:

Enterprise Value [ $101.4 M ]
(/) EBIT [ -$48.651 M ]
(=) EV/EBIT Ratio [ −2.1x ]

The tables below summarizes the trend in Cardiff Oncology’s EV/EBIT Ratio over the last five years:

Date Enterprise Value EBIT EV/EBIT Ratio
2020-12-31 $600.5 M -$16.878 M −35.6
2021-12-31 $121.4 M -$25.826 M −4.7
2022-12-31 -$48.907 M -$40.036 M 1.2
2023-12-31 -$12.946 M -$44.472 M 0.3
2024-12-31 $101.4 M -$48.651 M −2.1

Read more about enterprise value (ev) and ebit


Click the link below to download a spreadsheet with an example EV / EBIT calculation for Cardiff Oncology Inc below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-100.7x-50.7x-0.7x96.7x0200400600

The chart above depicts the distribution of ev / ebit for companies operating in the Healthcare sector in the Developed economic region. Over 2,355 companies were considered in this analysis, and 2,266 had meaningful values. The average ev / ebit of companies in the sector is 1.0x with a standard deviation of 18.8x.

Cardiff Oncology Inc's EV / EBIT of -2.1x ranks in the 38.8% percentile for the sector. The following table provides additional summary stats:

EV / EBIT In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,360
Included Constituents2,266
Min-101.7x
Max94.2x
Median-0.8x
Mean1.0x
Standard Deviation18.8x

You can find companies with similar ev / ebit using this stock screener.

All rights reserved. Terms Of Use